Abstract: Objective To explore the effect and Virology response of the combination of obipari and dasepvir in the treatment of chronic hepatitis C patients with genotype 1b, so as to provide reference for the selection of clinical treatment plans for chronic hepatitis C patients with genotype 1b. Method 136 patients with genotype 1b chronic hepatitis C in Nantong Third Hospital Affiliated to Nantong University from January 2019 to January 2022 were selected as the study subjects. Patients were treated with ombitasvir (ombitasvir/paritaprevir/ritonavir) 25/150/100mg once daily combined with dasubuvir 250 mg twice daily. All patients received a 12 week treatment regimen and were followed up for 24 weeks after the end of treatment. The virological response of the patients was evaluated at week 4, the end of treatment, 12 weeks and 24 weeks after the end of treatment, and the adverse reactions of the patients during the follow-up period were recorded. Result A total of 136 patients were enrolled, 75 were male (55.15%) and 61 were female (44.85%). Among them, 127 (93.38%) were newly diagnosed patients, 5 (3.68%) were treated with ombitasvir or dasubuvir, and 4 (2.94%) were treated with interferon. There were 10 patients (7.35%) with liver cirrhosis. All patients were followed up to 24 weeks after the end of treatment, and no death or loss of contact occurred. The virological response rate of patients was 100% (136/136) at the 4th week of treatment and 100% (136/136) at the end of treatment. The virological response rate was 100% (136/136) at 12 weeks after the end of treatment and 100% (136/136) at 24 weeks after the end of treatment. A total of 108 adverse events were reported, all of which were mild. No adverse events or deaths led to discontinuation of the study drug. Common adverse events and laboratory abnormalities that occurred were considered to be unrelated to the study drug, and no patients discontinued the study drug prematurely. Conclusion Ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C has a virological response rate of 100% and high safety.

Key words: Hepatitis C, Obipali, Daseboure, Virological response, Adverse reactions